National Cancer Institute (NCI): Mouth Neoplasms trials

The registry lists 23 Mouth Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 6 are open to participants now and 5 have results posted.

Phase 1 8Phase 2 12Phase 3 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingNCT07195734Phase 2
• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07156227Phase 1
• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerRecruitingNCT06980038Phase 2
• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingNCT06589804Phase 3
• Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruitingNCT05172245Phase 1
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedNCT03258554Phase 2/3Results posted
• ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive TreatmentTerminatedNCT02917629Phase 2Results posted
• Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant LesionActive, not recruitingNCT02581137Phase 2Results posted
• Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral LeukoplakiaCompletedNCT00330382Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT05172258Phase 2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take CisplatinActive, not recruitingNCT04533750Phase 1
• Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Cigarette Smoking and Oral MicrobiotaCompletedNCT01862809
• Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck CancerCompletedNCT01445405Phase 1
• Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck CancerCompletedNCT01254617Phase 1
• Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated ControlsActive, not recruitingNCT00867464
• Biomarkers for Oral CancerCompletedNCT00341497
• Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or PharynxCompletedNCT00064103Phase 1/2
• ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck CancerWithdrawnNCT00006106Phase 1